Composite type-2 biomarker strategy versus a symptom–risk-based algorithm to adjust corticosteroid dose in patients with severe asthma: a multicentre, single-blind, parallel group, randomised controlled trial
Published Online: 2021-01-?
Journal: The Lancet Respiratory Medicine•Publisher: Elsevier BV
Authors: Adel H Mansur•Adnam Azim•Andrew Menzies-Gow•Ashley Woodcock•Avril Horn•Beverley Hargadon•Catherine Borg•Catherine E Hanratty•Cecile T J Holweg•Chris J Corrigan•Christopher E Brightling•Clare Connolly•David F Choy•David Jackson•Dominic E Shaw•Douglas C Cowan•Douglas S Robinson•Freda Yang•Gabrielle Gainsborough•Gareth Davies•Geraldine Jones•Ian D Pavord•Ian M Adcock•James L Lordan•Joel Solis•John Busby•John G Matthews•Joseph R Arron•Katherine Smith•Kian F Chung•Liam G Heaney•Maria Nunez•Mary Bellamy•Michelle Bourne•Paula McCourt•Peter Bradding•Peter H Howarth•Ratko Djukanovic•Rekha Chaudhuri•Richard W Costello•Robert M Niven•Roisin Stone•Samantha M Walker•Sarah Davies•Sebastian Johnston•Stephen J Fowler•Tim W Harrison•Timothy C Hardman•Traceyanne Grandison•Val Hudson
